antihemophilic factor

(redirected from Kogenate)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to Kogenate: Xyntha

an·ti·he·mo·phil·ic factor

 (ăn′tē-hē′mə-fĭl′ĭk, ăn′tī-)
n. Abbr. AHF
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.antihemophilic factor - a coagulation factor (trade name Hemofil) whose absence is associated with hemophilia Aantihemophilic factor - a coagulation factor (trade name Hemofil) whose absence is associated with hemophilia A
clotting factor, coagulation factor - any of the factors in the blood whose actions are essential for blood coagulation
References in periodicals archive ?
Contract notice: Supply of medicinal products for uhkt - kogenate
M2 EQUITYBITES-May 12, 2014-Bayer receives approval from US FDA for Kogenate FS antihemophilic factor VIII (recombinant) for routine prophylaxis in adults with hemophilia A
M2 PHARMA-May 12, 2014-Bayer receives approval from US FDA for Kogenate FS antihemophilic factor VIII (recombinant) for routine prophylaxis in adults with hemophilia A
Sur le plan medical, le Kogenate qui a, depuis son introduction en Algerie, a ameliore, significativement, le traitement des hemophiles, fetera ses 25 annees d'existence cette annee.
2009) Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.
The company has a strong development program dedicated to hemophilia including ongoing clinical investigations into long-acting forms of Kogenate.
Sales of the Kogenate bleeding treatment rose 16% to 205 million euros, while sales of Betaseron for multiple sclerosis increased 10% to 264 million euros.
Factor product brand names by type Plasma-free Recombinant factor Refacto, Helixate FS, Kogenate FS, VIII Advate Recombinant Factor VIII Recombinate (PRODUCTS NO LONGER MANUFACTURED: BIOCLATE, HELIXATE, KOGENATE) Plasma-derived Factor VIII Hemofil M, Monarch M, Monoclate P, Alphanate, Humate P, Koate DVI Plasma-Derived von Willebrand- Humate P (may also use Koate DVI containing Factor VIII or Alphanate which contain von Willebrand Factor but are assayed in factor VIII units) Recombinant Factor IX Benefix Plasma-Derived Factor IX Alphanine, Mononine Desmopressin DDAVP, Stimate
Genentech's drug Kogenate, launched in 1993 to treat hemophilia, a disease affecting a total of 35,000 to 45,000 people in Western countries, grossed $400 million in 1999.
The drug Kogenate FS is the next generation blood-clotting factor that helps hemophiliacs survive.
He notes that over the next two years product launches will include the next generation of Kogenate, Bayer's lifesaving product for hemophilia patients, as well as new forms of fluoroquinolone-based antibiotics.
Current growth drivers include: Avalox/Avelox (moxifloxacin), Betaferon/Betaseron (interferon beta-1b), Kogenate (Factor VIII), Levitra (vardenafil), Mirena (levonorgestrel), Yasmin (ethinyloestradiol+drospirenone) and Aspirin Cardio.